Provided that, BAX and BAK are clinically relevant to the pathogenesis of colorectal cancer (Krajewska et al., 1996; Ogura et al., 1999; Bandrés et al., 2006), the findings of this study encourage to the search of novel prognostic and therapeutic strategies targeting the glycolytic pathway mediated by the BAX/BAK-XPC axis for improving the therapy of colon cancer, particularly for patients demonstrating the resistant phenotype. The gene discussed is BAX; the disease is colorectal cancer.